Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;39(10):2563-2567.
doi: 10.1038/s41375-025-02757-6. Epub 2025 Sep 10.

Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma

Sven Neubert #  1 , Umair Munawar #  1 , Julia Mersi  1 , Julia Noderer  1 , Silvia Nerreter  1 , Shilpa Kurian  1 , Seungbin Han  1 , Christina Verbruggen  1 , Emma Besant  1 , Nina Rein  1 , Max Köppel  1 , Johanna Lehmann  1 , Tabea Köhler  1 , Hannah Labinsky  1 , Sigrun Häusl  1 , Yoko Tamamushi  1 , Xiang Zhou  1 , Jule Pinter  2 , Anna Laura Herzog  2 , Kai Lopau  2 , Elion Hoxha  2 , Christoph Rummelt  3 , Elena Gerhard-Hartmann  4 , Andreas Rosenwald  4 , Torsten Steinbrunn  1   5 , Thomas Nerreter  1 , Michael Hudecek  1 , Hermann Einsele  1 , Leo Rasche  1   6 , K Martin Kortüm  1 , Johannes M Waldschmidt  7   8
Affiliations

Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma

Sven Neubert et al. Leukemia. 2025 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare the following competing interests: JMW reports personal fees from Janssen, Sanofi, Takeda, Pfizer, Oncopeptides, Menarini-Stemline, Skyline Dx and GSK, and research support from BMS. KMK reports personal fees from Celgene, BMS, AbbVie, GSK, and Takeda; grants and personal fees from Janssen. HE reports grants and other support from Janssen, BMS, Amgen, GSK, and Sanofi, as well as further support from Takeda and Novartis. LR reports personal fees from BMS, Janssen, Pfizer, Amgen, GSK and Sanofi. All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Multimodal debulking results in sBCMA clearance and subsequent response to BCMA× CD3 bispecific antibodies.
A Design of study including sBCMA-levels (ng/mL) in peripheral blood (PB), bone marrow (BM) and ultrafiltrate (UF) before and after plasmapheresis. B IgA levels in PB (mg/dL) and sBCMA levels (ng/mL) in BM and PB over the course of treatment, graphical view (upper panel), tabular view (lower panel). Abbreviations: Tec, teclistamab, PP plasmapheresis, D-P(A)CE daratumumab, cisplatin, cyclophosphamide, etoposide. Figure 1A created in BioRender under license https://BioRender.com/9gtlmss.
Fig. 2
Fig. 2. sBCMA limits in vitro efficacy of anti-BCMA immunotherapies.
A IL-2 (pg/mL) and B IFN-γ (pg/mL) levels were quantified by ELISA from co-culture supernatants after 20 h of incubation using ELISA MAX Deluxe Set for human IL-2 (431816, BioLegend) and human IFN-γ (430116, BioLegend). C Cytotoxic activity of belamaf was assessed in the presence of sBCMA using a luminescence-based viability assay with PBS as solvent control (**P < 0.005, ***P < 0.001, ****P < 0.0001). Abbreviations: IL-2 interleukin-2, IFN-γ interferon-gamma, cilta-cel ciltacabtagene autoleucel, BCMA B-cell maturation antigen, CAR chimeric antigen receptor, belamaf belantamab-mafodotin, solv. Ctr solvent control.
See this image and copyright information in PMC

References

    1. Waldschmidt JM, Rasche L, Kortüm KM, Einsele H. Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives. Clin Lymphoma Myeloma Leuk. 2024;S2152-2650:02423–6. - PubMed
    1. Da Vià MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27:616–9. - DOI - PubMed
    1. Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai Y-T, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12:868. - DOI - PMC - PubMed
    1. Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295–306. - DOI - PMC - PubMed
    1. Derrien J, Gastineau S, Frigout A, Giordano N, Cherkaoui M, Gaborit V, et al. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat Cancer. 2023;4:1536–43. - DOI - PubMed

LinkOut - more resources